Neuroprotection of rhGLP‐1 in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Preclinical Research & Development The purpose of the present study is to evaluate the neuroprotective effect of recombinant human glucagon‐like peptide‐1 (rhGLP‐1) as well as to explore corresponding mechanisms in diabetic rats with cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion (MCAO). Diabetes mellitus was induced by intraperitoneal injection of streptozotocin. The rats were pretreated with rhGLP‐1 (20 μg/kg intraperitoneally, thrice a day) for 14 days. Thereafter, the rats were subjected to MCAO 90 min/reperfusion 24 hr. At 2 and 24 hr of reperfusion, the rats were assessed for neurological deficits and subsequently executed for the evaluation of cerebral infarct volume, oxidative stress parameters, and the expression of excitatory amino acid transporter 2 (EAAT2) and apoptotic markers. Results indicate that rhGLP‐1 significantly ameliorated neurological deficits and reduced cerebral infarct volume in diabetic MCAO rats. In addition, oxidative stress parameters in ischemic penumbra were significantly alleviated in rhGLP‐1‐pretreated diabetic MCAO rats. rhGLP‐1 significantly upregulated the ratio of Bcl‐2/Bax and EAAT2 expression and downregulated cleaved caspase‐3 expression in ischemic penumbra of diabetic MCAO rats. Our results suggest that rhGLP‐1 could significantly ameliorate neurological deficits and reduce cerebral infarct volume in diabetic MCAO rats, which may be due to the inhibition of oxidative stress and apoptosis and the promotion of EAAT2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feigin, V. L., Forouzanfar, M. H., Krishnamurthi, R., Mensah, G. A., Connor, M., Bennett, D. A., Moran, A. E., Sacco, R. L., Anderson, L., Truelsen, T., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61953-4 · Cited by 3,899 · cited 1×
“Stroke has drawn great public attention recently owing to its high dis- ability rates and mortality, and caused a major threat to people's health and social development (Donnan, Fisher, Macleod, & Davis, 2008; Feigin et al., 2014).”
BackgroundExon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“…that GLP-1R has antiapoptotic properties, and studies have also presented that GLP-1 and exendin-4 strengthen cellular integrity and enhance total survival after exposure to fatty acids, cytokines, and peroxides (Harkavyi & Whitton, 2010; Hui, Nourparvar, Zhao, & Perfetti, 2003; Li et al., 2003).”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 3×
“models of both Parkinson's disease (PD) and ischemic stroke (Li et al., 2009; Li et al., 2010).”
BackgroundSelf-citationLauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464 · cited 2×
“Evidence has suggested that several oxidants and nitrides, including superoxide, peroxide, ammonia, and administration with β-amyloid, can lower glutamate transport activity of EAAT2 and downregulate astrocytic glutamate uptake (Lauderback et al., 2001; Trotti et al., 1998).”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 6×
“Moreover, GLP-1Rs widely distributed in brain tissue can produce neuroprotection to central nervous system and regulate neuronal activity (Banks, During, & Niehoff, 2004; Sharma, Jalewa, & Holscher, 2014).”
BackgroundInfluentialSharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120 · cited 2×
“In another study, liraglutide ameliorated behavioral scores and alleviated cerebral infarct volume and oxidative stress parameters as well as increasing cortical vascular endothelial growth factor levels (Sato et al., 2013).”
BackgroundOxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
Research works printed but not linked: 63
- 10.1053/j.gastro.2007.03.054 · DOI · Paper page
- 10.1124/jpet.103.063222 · DOI
- 10.1016/j.brainres.2011.10.026 · DOI
- 10.1016/j.neuroscience.2014.09.064 · DOI
- 10.1007/s00125-004-1379-6 · DOI · Paper page
- 10.1038/s41598-017-02838-2 · DOI · Paper page
- 10.1007/s11064-004-6869-x · DOI · Paper page
- 10.1016/S0753-3322(98)80012-7 · DOI
- 10.1038/jcbfm.2009.47 · DOI · Paper page
- 10.1016/j.neuroscience.2013.10.038 · DOI
- 10.3390/ijms12107199 · DOI · Paper page
- 10.1161/01.STR.0000252091.36912.65 · DOI · Paper page
- Dinkova‐Kostova A. T., 2008, Direct and indirect antioxidant properties of inducers of cytoprotective proteins, Molecular Nutrition & Food Research, 52, S128
- 10.1016/S0140-6736(08)60694-7 · DOI · Paper page
- 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
- 10.2337/diabetes.53.2007.S96 · DOI · Paper page
- 10.1023/B:NERE.0000014832.78725.1a · DOI
- 10.1016/S0165-3806(01)00303-0 · DOI
- 10.1016/j.neurobiolaging.2010.02.014 · DOI · Paper page
- 10.1371/journal.pone.0089450 · DOI · Paper page
- 10.1161/01.STR.0000106916.81680.C0 · DOI
- 10.1038/sj.bjp.0707594 · DOI · Paper page
- 10.1007/978-3-7091-0693-8_49 · DOI
- 10.1097/WNR.0000000000000490 · DOI · Paper page
- 10.1111/j.1476-5381.2009.00486.x · DOI · Paper page
- 10.1371/journal.pone.0022135 · DOI · Paper page
- 10.1089/152308604771978372 · DOI
- 10.1530/JOE-13-0221 · DOI · Paper page
- 10.1111/j.1460-9568.2004.03554.x · doi:10.1111/j.1460-9568.2004.03554.x
- 10.1210/en.2002-220897 · DOI · Paper page
- 10.1001/archneur.58.8.1209 · DOI · Paper page
- 10.1002/jnr.22596 · DOI · Paper page
- 10.3233/JAD-2010-1314 · DOI · Paper page
- 10.1152/physrev.1999.79.4.1431 · DOI · Paper page
- 10.1161/01.STR.20.1.84 · DOI · Paper page
- 10.1016/S1474-4422(12)70005-4 · DOI · Paper page
- 10.1016/j.neuint.2012.11.009 · DOI · Paper page
- 10.1002/ana.410420310 · DOI · Paper page
- 10.1007/s10735-007-9102-9 · DOI
- 10.1016/j.devcel.2011.06.017 · DOI · Paper page
- 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
- 10.1007/s12035-007-8013-9 · DOI · Paper page
- 10.1155/2012/493934 · DOI
- 10.1007/978-3-319-08894-5_9 · DOI
- 10.1016/j.expneurol.2006.09.028 · DOI · Paper page
- 10.1124/jpet.300.3.958 · DOI · Paper page
- 10.1002/jnr.10611 · DOI · Paper page
- 10.1111/j.1460-9568.2001.01367.x · doi:10.1111/j.1460-9568.2001.01367.x · Paper page
- 10.1016/0896-6273(94)90038-8 · DOI · Paper page
- Ryden L., 2007, Guidelines on diabetes, pre‐diabetes, and cardiovascular diseases: Executive summary. The Task Force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), European Heart Journal, 28, 88
- 10.1016/S0006-8993(03)03117-2 · DOI
- 10.1089/ars.2010.3292 · DOI
- 10.1038/348443a0 · DOI · Paper page
- 10.1111/j.1440-1681.2004.04017.x · DOI · Paper page
- 10.1007/BF00241964 · DOI
- 10.1016/S0165-6147(98)01230-9 · DOI · Paper page
- 10.1016/S0140-6736(12)60738-7 · DOI · Paper page
- 10.1046/j.1460-9568.1998.00108.x · DOI · Paper page
- 10.1016/S0165-0270(98)00067-3 · DOI
- 10.1016/j.ejps.2015.01.010 · DOI
- 10.3390/molecules17032725 · doi:10.3390/molecules17032725
- 10.1046/j.1471-4159.2003.01756.x · DOI · Paper page
- 10.1016/j.brainres.2015.01.014 · DOI
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The anti-apoptotic effect of GLP-1R agonism has been demonstrated in vivo in mice [543,550,551] and rats [552,553] as well as in several rodent [550,551] and human [554,555] cell lines, purified rat b-cells [543], and humans [556].”
BackgroundGlucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
“In diabetic rats with cerebral ischemia/reperfusion damage caused by middle cerebral artery occlusion, recombinant GLP-1 improved neurological deficit and reduced cerebral infarct area, mainly through the inhibition of oxidative stress and apoptosis (Fang et al., 2018).”
BackgroundYang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
Metadata
- Authors
- Fang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2018-09
- Volume
- 79
- Issue
- 6
- Pages
- 249-259
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2891027425
- Cited by
- 21
- References
- 9
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Funders
- Peking University
- Research and Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.